Xelafaslatide

N/A

Report date: 2025/05/22 15:16:45
NMEFirst In Class

Base Information

Drug NameXelafaslatide
Drug Alias NameONL-1204
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionApoptosis-mediating surface antigen FAS inhibitorsSoluble Fas ligand inhibitorsApoproteins inhibitors +[4] 
TargetsApoptosis-mediating surface antigen FASSoluble Fas ligandApoproteins
Therapy Area/IndicationsRetinal DetachmentGeographic AtrophyMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNew Zealand +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOnl Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesOnl Therapeutics
Inactive CompaniesN/A
Active IndicationsRetinal DetachmentGeographic AtrophyMacular Degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A